This article compares finance roles in startups and corporates across skills, growth, and work culture. The key takeaway is that career fit matters more than brand or salary ...

The Nasdaq Composite rallied late on Tuesday to snap its losing streak at three days. The tech-heavy index rose 0.2% after falling nearly 0.6% at its low earlier in the day. The S&P 500 dipped 0.2%.

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

The recent 30% drop in CoreWeave’s stock (NASDAQ: CRWV) is warranted due to a mix of short-term execution challenges and notable balance sheet risks. Although the primary narrative of substantial AI ...

A day after Thursday’s anxiety-inducing fake out, Friday turned into Redemption Day on Wall Street. The Dow ended the day 493 points higher, or 1.08%, after gaining as much as 800 points earlier in ...

Growing concerns about an artificial intelligence bubble have, in large part, caused the stock market’s recent bout of volatility. So the AI industry will face an enormous test when Nvidia, the ...

Wedbush analyst Scott Devitt shrugs off concerns about rising capital expenditures, noting that artificial intelligence is already boosting Meta's advertising engine Meta joins Apple, Tesla and ...

Strategy (Nasdaq: MSTR), formerly MicroStrategy, has seen its fortune decline of late as the leading Bitcoin (BTC) treasury's stock has dropped by a drastic 60% from its peak. The MSTR stock is ...

Apple (NASDAQ: AAPL) stock is trading near its 52-week high, which is raising concerns about overvaluation from investors. Where to invest $1,000 right now? Our analyst team just revealed what they ...

IBM stock plunged after publishing its third-quarter financial results. The company’s software revenue, which includes its AI initiatives, is struggling. There are signs that IBM is losing the AI race ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled ...